Why the study?
Updated recommendations for CKD assessment including cystatin C use and combined GFR equations were introduced in the 2024 KDIGO guideline to improve detection and monitoring.
Implementation of the 2024 KDIGO recommendations, including cystatin C testing and combined GFR equations, is expected to improve diagnostic precision and personalized CKD risk stratification.
Adopt 2024 KDIGO cystatin C and combined GFR equations where indicated; leaves open local validation of EKFC and KFRE standardization.
Summary: Chronic kidney disease (CKD) affects over 800 million people globally, and laboratory testing is essential for its detection and monitoring. The 2024 KDIGO guideline introduces updated recommendations for assessing kidney function, including the mandatory use of cystatin C in certain clinical contexts and the application of combined GFR estimation equations. The EKFC equation is favored for European populations. Accurate testing, standardization, and use of the KFRE tool are key to personalized CKD risk stratification. Implementing these recommendations will improve diagnostic precision and support interdisciplinary patient management.
No takes yet. Share an insight, caveat, or question.
Maksymyuk et al. (2025) conducted a review in Chronic kidney disease. KDIGO 2024 guidelines was evaluated. The 2024 KDIGO guidelines recommend the mandatory use of cystatin C in certain clinical contexts and the application of combined GFR estimation equations to improve diagnostic precision in CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: